Is this your company? Get featured or correct your listing →
Company Snapshot
Attovia Therapeutics is a biotech company, based in San Carlos, CA, founded 2023. Total funding ~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026) (As of Aug 2026).
Recent changes
- Aug 10, 2026Aug 10, 2026Attovia Therapeutics Climbs 29% After $289M IPO Pulse story
- Aug 5, 2026Aug 5, 2026IPO $289M at $767M Value Add Pulse enrichment
- Aug 5, 2026Aug 5, 2026First reported valuation: $767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026)Estimated Value Add Pulse enrichment
- Aug 2026Aug 2026First reported total funding: ~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026)Estimated Value Add Pulse enrichment
- Apr 15, 2025Apr 15, 2025Raised $90M Series C Value Add Pulse enrichment
Earlier changes (1)
- Jun 1, 2023Jun 1, 2023Raised $60M Series A Value Add Pulse enrichment
Funding history
2 equity events · newest first · sources dated per row| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Apr 15, 2025 | Series Cnot counted: no linked source | $90M | — | — | Value Add Pulse research |
| Jun 2023 | Series Anot counted: no linked source | $60M | — | — | Value Add Pulse research |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
Debt, IPO & other events
not counted in equity raised| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Aug 5, 2026 | ipo | $289M | $767M | Value Add Pulse research |
Investors
Latest Pulse
- Oct 14, 2026Frazier Life Sciences II Prices $75M IPO, Lists FLSCFrazier Life Sciences Acquisition Corp. II priced its $75M IPO at $10 a share, with shares beginning Nasdaq trading under ticker FLSC on October 14.→
- Aug 10, 2026Biotech IPO Window Closes Its Strongest Week Since SpringBlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.→
- Aug 10, 2026Attovia Therapeutics Climbs 29% After $289M IPOAttovia Therapeutics priced an upsized $289 million IPO and climbed 29% on debut, the fourth biotech in two weeks to price well above its original terms.→
- Aug 7, 2026BlossomHill Prices Upsized $150M IPO, Debuts on NasdaqBlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.→
- Aug 5, 2026Braveheart Bio Prices $300M IPO for Heart DrugBraveheart Bio priced 18.75M shares at $16 to raise $300M on Nasdaq, funding its lead drug BHB-1893 for hypertrophic cardiomyopathy in the same week two other biotechs also priced.→
- Aug 5, 2026Why 217 IPOs Still Doesn't Mean the Window Is OpenThe US has produced 217 IPOs in 2026, up 6.9% year over year, and almost none of them are venture-backed technology companies -- which is why the count says nothing useful about exit liquidity.→
- Aug 5, 2026Goldman-Backed Attovia Prices IPO, Lists on NasdaqAttovia Therapeutics priced its IPO at $17/share, raising roughly $212.5M, and began trading on Nasdaq today under ATTO -- another test of whether biotech's IPO window is genuinely reopening.→
- Aug 5, 2026Attovia Prices $289M Nasdaq IPO at $17 a ShareAttovia Therapeutics priced 17 million shares at $17 to raise $289M on Nasdaq under the ticker ATTO, the largest operating-company listing of the first week of August.→
- Aug 4, 2026Attovia Prices IPO as Biotech's Public Pipeline Fills OutAttovia Therapeutics priced its Nasdaq IPO at $17 a share while Latigo Biotherapeutics advances its own S-1, the latest signs that the biotech listing window is filling with genuine clinical-stage pipelines.→
- Aug 3, 2026Blue Owl-Backed Latigo Advances Nasdaq IPO PlansLatigo Biotherapeutics filed an amended S-1 this week, advancing its Nasdaq IPO to fund a pivotal Phase 3 trial for its non-opioid pain drug ahead of the trial itself starting.→
Coverage Timeline
newest first- Aug 10, 2026IPOBiotech IPO Window Closes Its Strongest Week Since Spring~$972M, 4 deals→
- Aug 10, 2026IPOAttovia Therapeutics Climbs 29% After $289M IPO$289M IPO→
- Aug 5, 2026IPOGoldman-Backed Attovia Prices IPO, Lists on Nasdaq~$212.5M raised→
- Aug 5, 2026IPOAttovia Prices $289M Nasdaq IPO at $17 a Share$289M IPO→
- Aug 4, 2026IPOAttovia Prices IPO as Biotech's Public Pipeline Fills Out$17/share IPO→
- Jul 29, 2026IPOGoldman-Backed Attovia Sets Terms for $200M Nasdaq IPO$200M target IPO→
- Jul 29, 2026IPOGoldman-Backed Attovia Seeks $212.5M in Biotech IPO$212.5M IPO→
- Jul 14, 2026IPOTwo New Biotech IPO Filings Land in One Week2 S-1s, same week→
All Coverage
IPO~$972M, 4 deals
Biotech IPO Window Closes Its Strongest Week Since Spring
BlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.
FOLLOW-UP
Attovia Therapeutics Climbs 29% After $289M IPO
IPO$289M IPO
Attovia Therapeutics Climbs 29% After $289M IPO
Attovia Therapeutics priced an upsized $289 million IPO and climbed 29% on debut, the fourth biotech in two weeks to price well above its original terms.
FOLLOW-UP
Goldman-Backed Attovia Prices IPO, Lists on Nasdaq
IPO~$212.5M raised
Goldman-Backed Attovia Prices IPO, Lists on Nasdaq
Attovia Therapeutics priced its IPO at $17/share, raising roughly $212.5M, and began trading on Nasdaq today under ATTO -- another test of whether biotech's IPO window is genuinely reopening.
Attovia Prices $289M Nasdaq IPO at $17 a Share
IPO$289M IPO
Attovia Prices $289M Nasdaq IPO at $17 a Share
Attovia Therapeutics priced 17 million shares at $17 to raise $289M on Nasdaq under the ticker ATTO, the largest operating-company listing of the first week of August.
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
IPO$17/share IPO
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
Attovia Therapeutics priced its Nasdaq IPO at $17 a share while Latigo Biotherapeutics advances its own S-1, the latest signs that the biotech listing window is filling with genuine clinical-stage pipelines.
Goldman-Backed Attovia Sets Terms for $200M Nasdaq IPO
IPO$200M target IPO
Goldman-Backed Attovia Sets Terms for $200M Nasdaq IPO
Attovia Therapeutics set terms for a Nasdaq IPO, offering 12.5 million shares at $15-17 to raise up to $212.5 million, advancing its Phase 1 itch and eczema drug candidates toward a public listing under ticker ATTO.
Goldman-Backed Attovia Seeks $212.5M in Biotech IPO
IPO$212.5M IPO
Goldman-Backed Attovia Seeks $212.5M in Biotech IPO
Attovia Therapeutics is seeking up to $212.5 million in a US IPO, offering 12.5 million shares at $15-$17 each, backed by Goldman Sachs Alternatives, Deep Track Capital, Frazier Life Sciences, and venBio.
Two New Biotech IPO Filings Land in One Week
IPO2 S-1s, same week
Two New Biotech IPO Filings Land in One Week
Braveheart Bio and Attovia Therapeutics both filed S-1s the same week, adding two names to 2026's biotech IPO pipeline amid the strongest H1 biotech venture funding since 2022.
Value Add Research
Related Companies
Sources & methodologyshow
Where these figures come from
- Value Add Pulse researchValue Add VC data4 facts
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.